ATE174515T1 - Verwendung eines cdw52-spezifischen antikörpers zur behandlung von durch t-zellen vermittelten gelenkentzündungen - Google Patents

Verwendung eines cdw52-spezifischen antikörpers zur behandlung von durch t-zellen vermittelten gelenkentzündungen

Info

Publication number
ATE174515T1
ATE174515T1 AT93908763T AT93908763T ATE174515T1 AT E174515 T1 ATE174515 T1 AT E174515T1 AT 93908763 T AT93908763 T AT 93908763T AT 93908763 T AT93908763 T AT 93908763T AT E174515 T1 ATE174515 T1 AT E174515T1
Authority
AT
Austria
Prior art keywords
treatment
cdw52
cell
specific antibody
antibody
Prior art date
Application number
AT93908763T
Other languages
English (en)
Inventor
Herman Waldmann
Geoffrey Hale
Original Assignee
Btg Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929215749A external-priority patent/GB9215749D0/en
Application filed by Btg Int Ltd filed Critical Btg Int Ltd
Application granted granted Critical
Publication of ATE174515T1 publication Critical patent/ATE174515T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT93908763T 1991-10-15 1992-10-14 Verwendung eines cdw52-spezifischen antikörpers zur behandlung von durch t-zellen vermittelten gelenkentzündungen ATE174515T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77559891A 1991-10-15 1991-10-15
GB929215749A GB9215749D0 (en) 1992-07-24 1992-07-24 Medicaments

Publications (1)

Publication Number Publication Date
ATE174515T1 true ATE174515T1 (de) 1999-01-15

Family

ID=26301317

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93908763T ATE174515T1 (de) 1991-10-15 1992-10-14 Verwendung eines cdw52-spezifischen antikörpers zur behandlung von durch t-zellen vermittelten gelenkentzündungen

Country Status (12)

Country Link
EP (1) EP0610447B1 (de)
JP (1) JP3535155B2 (de)
KR (1) KR100264218B1 (de)
AT (1) ATE174515T1 (de)
AU (1) AU671807B2 (de)
CA (1) CA2120911A1 (de)
DE (1) DE69227918T2 (de)
DK (1) DK0610447T3 (de)
ES (1) ES2125977T3 (de)
IL (1) IL103418A (de)
MY (1) MY115415A (de)
WO (1) WO1993007899A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB9603507D0 (en) 1996-02-20 1996-04-17 Isis Innovation Antibody variants
GB2380127A (en) 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
EP4541818A3 (de) * 2012-05-25 2025-07-23 Cellectis Verfahren zur züchtung von allogener und immunosuppressiver resistenter t-zelle zur immuntherapie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68909441T2 (de) * 1988-02-12 1994-02-10 British Tech Group Modifizierte Antikörper.
DE69028713T3 (de) * 1989-12-27 2004-05-13 Centocor, Inc. Schimäre immunoglobuline für cd4-rezeptoren
GB9022547D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin

Also Published As

Publication number Publication date
IL103418A0 (en) 1993-03-15
AU2698592A (en) 1993-05-21
JPH07500330A (ja) 1995-01-12
KR100264218B1 (ko) 2000-08-16
MY115415A (en) 2003-06-30
EP0610447B1 (de) 1998-12-16
JP3535155B2 (ja) 2004-06-07
DE69227918T2 (de) 1999-05-12
CA2120911A1 (en) 1993-04-29
EP0610447A1 (de) 1994-08-17
WO1993007899A1 (en) 1993-04-29
DE69227918D1 (de) 1999-01-28
DK0610447T3 (da) 1999-08-23
AU671807B2 (en) 1996-09-12
IL103418A (en) 1997-11-20
ES2125977T3 (es) 1999-03-16

Similar Documents

Publication Publication Date Title
DE69228556D1 (de) CDw52-SPEZIFISCHER ANTIKÖRPER ZUR BEHANDLUNG VON MULTIPLER SKLEROSE
GB2294267A (en) Antibody fragments in therapy
ATE197316T1 (de) Monoklonale antikörper gegen definiierte regionen des t-zell-antigenrezeptors
DE69733960D1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
PT699755E (pt) Metodo para obtencao de imunoglobulinas modificadas com imunogenicidade reduzida de dominios variaveis de anticorpos de murideo composicoes que as contem
DE69132045D1 (de) Monoklonale Antikörper gegen menschlichen Tumornekrosefaktor alpha
ATE95068T1 (de) Modifizierte antikoerper.
ATE233814T1 (de) Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus
AU3208397A (en) Mutated nonactivating igg2 domains and anti-cd3 antibodies incorporating the same
LU92048I2 (fr) Tocilizumab
DE69632465D1 (de) Cdr-transplantierte antikörper gegen "tissue factor" und verfahren zur deren verwendung
AU628948B2 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
DE69129460D1 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
GR3029774T3 (en) Method of preparing a radioactive rhenium complex solution.
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
EA200400930A1 (ru) Блокирующее моноклональное антитело к vla-1 или его применение для лечения воспалительных заболеваний
DE69227918D1 (de) VERWENDUNG EINES CDw52-SPEZIFISCHEN ANTIKÖRPERS ZUR BEHANDLUNG VON DURCH T-ZELLEN VERMITTELTEN GELENKENTZÜNDUNGEN
FI930106A0 (fi) Cenp-b-epitop
AU584690B2 (en) E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma
WO1996040250A3 (en) Platelet-specific chimeric immunoglobulin and methods of use therefor
WO2024039672A3 (en) Antibodies against msln and methods of use thereof
FI942392L (fi) Peptidejä ja vasta-aineita nivelreuman hoitoon
ATE134649T1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids- verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
ATE184315T1 (de) Neuartiges endothelzell-molekül, das die bindung von lymphozyten im menschen vermittelt
DE69329109D1 (de) Nachweisverfahren für adrenale autoantikörper

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification